These outcomes reflect observations of patient resistance to PD-1 blockade and IDO inhibitor therapy in NSCLC and other cancers,24–26 and testify to the key roles of the PD-1 and IDO pathways in promoting resistance to CDA therapy. Here, IDO1 is linked to non-small cell lung carcinoma.